![Debut de amiloidosis AL con afectación grave cardíaca y renal: una asociación poco frecuente de infausto pronóstico. A raíz de 2 casos | Nefrología Debut de amiloidosis AL con afectación grave cardíaca y renal: una asociación poco frecuente de infausto pronóstico. A raíz de 2 casos | Nefrología](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/X0211699512002118:11556_19759_31911_es_11556_t1.jpg?idApp=UINPBA000064)
Debut de amiloidosis AL con afectación grave cardíaca y renal: una asociación poco frecuente de infausto pronóstico. A raíz de 2 casos | Nefrología
Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians | Italian Journal of Medicine
![Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases - Garcia‐Pavia - 2021 - European Journal of Heart Failure - Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases - Garcia‐Pavia - 2021 - European Journal of Heart Failure -](https://onlinelibrary.wiley.com/cms/asset/315ddae6-3416-4884-8a50-3bae630ac826/ejhf2140-fig-0004-m.jpg)
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases - Garcia‐Pavia - 2021 - European Journal of Heart Failure -
![Cardiac Amyloidosis: The Importance of a Multidisciplinary Approach | Revista Española de Cardiología Cardiac Amyloidosis: The Importance of a Multidisciplinary Approach | Revista Española de Cardiología](https://multimedia.elsevier.es/PublicationsMultimediaV1/item/multimedia/13139390:255v62n06-13139390fig1.jpg?idApp=UINPBA000025)
Cardiac Amyloidosis: The Importance of a Multidisciplinary Approach | Revista Española de Cardiología
![How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis) - Clinical Lymphoma, Myeloma and Leukemia How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis) - Clinical Lymphoma, Myeloma and Leukemia](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f23db638-b58c-4358-b132-0b7815169109/gr1_lrg.jpg)
How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis) - Clinical Lymphoma, Myeloma and Leukemia
![Systemic amyloidosis from A (AA) to T (ATTR): a review - Muchtar - 2021 - Journal of Internal Medicine - Wiley Online Library Systemic amyloidosis from A (AA) to T (ATTR): a review - Muchtar - 2021 - Journal of Internal Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d3ed9bd6-c675-4e46-aadb-25d919f5abbe/joim13169-toc-0001-m.jpg)